To our surprise, for several of these subcategories exenatide and sitagliptin apparently significantly reduced the odds ratios, in the case of exenatide, for example, regarding lung cancer, prostate cancer, lymphoma/multiple myeloma, metastasising tumors of unknown origin, and other tumours not specified. Sitagliptin significantly reduced the odds ratios for colon cancer, prostate cancer, and other tumours not specified. On the other hand, with exenatide treatment the rate of reporting carcinoid and stromal tumors and tumors of the female genital tract was apparently significantly elevated, and with sitagliptin treatment leukemias appeared to be reported significantly more often
Hot flashes are one of the most common symptoms of menopause
Rapid glucocorticoid effects on immune cells
By following the right steps after a missed dose , you can help keep your blood sugar levels under control and reduce the risk of complications
Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL